IBRX Q4 2021 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$390,000+1757.1% YoY

Gross Profit

$390,000100.0% margin

Operating Income

-$79M-20326.7% margin

Net Income

-$91M-23399.7% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+490.9%

Cash Flow

Operating Cash Flow

-$72M

Free Cash Flow

-$82M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$469M

Total Liabilities

$713M

Stockholders' Equity

-$242M

Cash & Equivalents

$181M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$390,000	$21,000	+1757.1%
Gross Profit	$390,000	-$2M	+117.5%
Operating Income	-$79M	-$31M	-156.7%
Net Income	-$91M	-$32M	-184.0%